D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on
animal and human studies, timed bromocriptine administration within 2 h of awakening is …

Objective: To review the pharmacologic characteristics, safety, and efficacy of bromocriptine
mesylate for glycemic control in patients with type 2 diabetes mellitus. Data Sources: A …

TERMINOLOGY AND PRINCIPLES OF COMBINING ANTIPSYCHOTICS WITH A SECOND
MEDICATION: The term “combination” includes virtually all the ways in which one …

Background Bromocriptine‐QR (a quick‐release formulation of bromocriptine mesylate), a
dopamine D2 receptor agonist, is a US F ood and D rug A dministrration–approved …

The number of agents available to improve glycemic control in patients with diabetes has
increased substantially in recent years. Only 15 years ago, available therapies included only …

Objective: To compare the effectiveness and safety of add on therapy of bromocriptine with
metformin in type 2 diabetes mellitus (DM) patients. Material and Methods: Adult type 2 DM …

Aims: To evaluate the glycemic control efficacy and cardio-metabolic safety of bromocriptine-
quick release (Bromocriptine-QR) among subjects with type 2 diabetes who were taking a …

The prevalence of obesity has increased to pandemic levels worldwide and is related to
increased risk of morbidity and mortality. Metabolic comorbidities are commonly associated …

Cardiovascular risk reduction is a key priority in patients with diabetes. The relationship
between glycemic control and macrovascular outcomes, such as the benefit of intensive …

El término «combinación» incluye prácticamente todas las modalidades en las que una
medicación puede añadirse a otra. Los otros términos de uso frecuente son «aumento» …